IMXQB-80 : A Quillaja brasiliensis saponin-based nanoadjuvant enhances Zika virus specific immune responses in mice
Copyright © 2020 Elsevier Ltd. All rights reserved..
Vaccine adjuvants are compounds that enhance/prolong the immune response to a co-administered antigen. Saponins have been widely used as adjuvants for many years in several vaccines - especially for intracellular pathogens - including the recent and somewhat revolutionary malaria and shingles vaccines. In view of the immunoadjuvant potential of Q. brasiliensis saponins, the present study aimed to characterize the QB-80 saponin-rich fraction and a nanoadjuvant prepared with QB-80 and lipids (IMXQB-80). In addition, the performance of such adjuvants was examined in experimental inactivated vaccines against Zika virus (ZIKV). Analysis of QB-80 by DI-ESI-ToF by negative ion electrospray revealed over 29 saponins that could be assigned to known structures existing in their congener Q. saponaria, including the well-studied QS-21 and QS-7. The QB-80 saponins were a micrOTOF able to self-assembly with lipids in ISCOM-like nanoparticles with diameters of approximately 43 nm, here named IMXQB-80. Toxicity assays revealed that QB-80 saponins did present some haemolytical and cytotoxic potentials; however, these were abrogated in IMXQB-80 nanoparticles. Regarding the adjuvant activity, QB-80 and IMXQB-80 significantly enhanced serum levels of anti-Zika virus IgG and subtypes (IgG1, IgG2b, IgG2c) as well as neutralized antibodies when compared to an unadjuvanted vaccine. Furthermore, the nanoadjuvant IMXQB-80 was as effective as QB-80 in stimulating immune responses, yet requiring fourfold less saponins to induce the equivalent stimuli, and with less toxicity. These findings reveal that the saponin fraction QB-80, and particularly the IMXQB-80 nanoadjuvant, are safe and capable of potentializing immune responses when used as adjuvants in experimental ZIKV vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Vaccine - 39(2021), 3 vom: 15. Jan., Seite 571-579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cibulski, Samuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2020.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319045730 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319045730 | ||
| 003 | DE-627 | ||
| 005 | 20231225170627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2020.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319045730 | ||
| 035 | |a (NLM)33339669 | ||
| 035 | |a (PII)S0264-410X(20)31567-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cibulski, Samuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IMXQB-80 |b A Quillaja brasiliensis saponin-based nanoadjuvant enhances Zika virus specific immune responses in mice |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Vaccine adjuvants are compounds that enhance/prolong the immune response to a co-administered antigen. Saponins have been widely used as adjuvants for many years in several vaccines - especially for intracellular pathogens - including the recent and somewhat revolutionary malaria and shingles vaccines. In view of the immunoadjuvant potential of Q. brasiliensis saponins, the present study aimed to characterize the QB-80 saponin-rich fraction and a nanoadjuvant prepared with QB-80 and lipids (IMXQB-80). In addition, the performance of such adjuvants was examined in experimental inactivated vaccines against Zika virus (ZIKV). Analysis of QB-80 by DI-ESI-ToF by negative ion electrospray revealed over 29 saponins that could be assigned to known structures existing in their congener Q. saponaria, including the well-studied QS-21 and QS-7. The QB-80 saponins were a micrOTOF able to self-assembly with lipids in ISCOM-like nanoparticles with diameters of approximately 43 nm, here named IMXQB-80. Toxicity assays revealed that QB-80 saponins did present some haemolytical and cytotoxic potentials; however, these were abrogated in IMXQB-80 nanoparticles. Regarding the adjuvant activity, QB-80 and IMXQB-80 significantly enhanced serum levels of anti-Zika virus IgG and subtypes (IgG1, IgG2b, IgG2c) as well as neutralized antibodies when compared to an unadjuvanted vaccine. Furthermore, the nanoadjuvant IMXQB-80 was as effective as QB-80 in stimulating immune responses, yet requiring fourfold less saponins to induce the equivalent stimuli, and with less toxicity. These findings reveal that the saponin fraction QB-80, and particularly the IMXQB-80 nanoadjuvant, are safe and capable of potentializing immune responses when used as adjuvants in experimental ZIKV vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Immune system | |
| 650 | 4 | |a Nanoadjuvant | |
| 650 | 4 | |a Quillaja brasiliensis | |
| 650 | 4 | |a Saponins | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a Zika virus | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Quillaja Saponins |2 NLM | |
| 650 | 7 | |a Saponins |2 NLM | |
| 700 | 1 | |a Teixeira, Thais Fumaco |e verfasserin |4 aut | |
| 700 | 1 | |a Varela, Ana Paula Muterle |e verfasserin |4 aut | |
| 700 | 1 | |a de Lima, Matheus Fabião |e verfasserin |4 aut | |
| 700 | 1 | |a Casanova, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Yuri Mangueira |e verfasserin |4 aut | |
| 700 | 1 | |a Fechine Tavares, Josean |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Marcelo Sobral |e verfasserin |4 aut | |
| 700 | 1 | |a Sesterheim, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Diogo Onofre |e verfasserin |4 aut | |
| 700 | 1 | |a Roehe, Paulo Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Silveira, Fernando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 39(2021), 3 vom: 15. Jan., Seite 571-579 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:3 |g day:15 |g month:01 |g pages:571-579 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2020.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 3 |b 15 |c 01 |h 571-579 | ||